Combination of bupropion and a second compound for affecting weight loss

Details for Australian Patent Application No. 2005271574 (hide)

Owner Orexigen Therapeutics, Inc.

Inventors Cowley, Michael Alexander; Weber, Eckard

Agent Cullen & Co

Pub. Number AU-A-2005271574

PCT Pub. Number WO2006/017504

Priority 60/598,558 03.08.04 US

Filing date 1 August 2005

Wipo publication date 16 February 2006

International Classifications

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

Event Publications

8 March 2007 PCT application entered the National Phase

  PCT publication WO2006/017504 Priority application(s): WO2006/017504

2 July 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005271581-Sonar imaging system for mounting to watercraft

2005271573-Conveyor track or container lubricant compositions